Neuron BPh and the Medina foundation join forces to publicize their technologies and pre-clinical research services for the pharmaceutical industry
The agreement will promote the increase of synergies between the two companies for the development of new drugs and innovative therapies.
The biotech company Neuron BPh and the Medina foundation have signed an agreement for joint activities and promotion. The companies, which are both located in the Health-Sciences Technological Park of Granada, aim to expand their technologies by offering complete services for the development of pre-clinical research projects with the best professionals from each division.
The Medina foundation has over 50 years of experience in the field of drug discovery originating from natural products and the pre-clinical evaluation of pharma candidates from the former Merck Basic Research Centre of Merck Sharp and Dohme.
The foundation develops lines for the discovery of new compounds extracted from microbial natural products, which will fulfil unmet medical needs in areas of therapeutic priority. It also offers a wide experience in pre-clinical evaluation studies for cardio-vascular risk and adverse effects caused by the metabolism of drugs via its platform for safety and toxicity assays.
The BioPhama Division of Neuron BPh offers pre-clinical research in vitro studies, studies in safety and efficiency using zebrafish and assays in rodents. The Neuron Group is basing its growth on partnerships with other leading companies in the fields of pharmacy, energy and agro-food, focusing on the development of new products with the aim of strengthening its commercial activities.